Chemoprevention of pancreatic cancer using a combinatorial nano-drug system

使用组合纳米药物系统化学预防胰腺癌

• 批准号: 8115727
• 负责人: SUNIL PRABHU
• 金额: $ 7.45万
• 依托单位: WESTERN UNIVERSITY OF HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-02-17 至 2013-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8115727
• 关键词: Adverse effects; Affect; American; American Cancer Society; Animal Model; Anti-Inflammatory Agents; Anti-inflammatory; Antineoplastic Agents; Apoptosis; Area; Aspirin; Attention; Biological Availability; Blood Circulation; Cancer Etiology; Cancer cell line; Cell Proliferation; Cell Survival; Cessation of life; Chemoprevention; Chemopreventive Agent; Colon Carcinoma; Colorectal Cancer; Combined Modality Therapy; Coupled; Curcumin; Data; Diagnosis; Disadvantaged; Disease; Dose; Drug Combinations; Drug Delivery Systems; Drug Formulations; Encapsulated; Exhibits; Future; Goals; Hamsters; Hepatic; Immune; In Vitro; Inflammatory; Kidney; Lipids; Literature; Malignant neoplasm of pancreas; Measures; Metabolism; Modality; Nanotechnology; Oral; Organ; Pancreas; Pancreatic carcinoma; Particle Size; Pathway interactions; Patients; Performance; Pharmaceutical Preparations; Pilot Projects; Polymers; Prevention; Rattus; Relative (related person); Severities; Site; Solid; Sulforaphane; System; Technology; Therapeutic; Time; Toxic effect; United States; Work; base; cancer chemoprevention; cancer prevention; clinical application; combinatorial; design; fighting; in vivo; interest; lymphatic circulation; nanodrug; nanoparticle; novel; outcome forecast; pancreatic cancer cells; poly(lactide); prevent; response

DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth most common cause of cancer deaths in the United States with over 42,000 diagnosed with this disease every year. The prognosis is extremely grim for affected patients with <5% chance of survival within 5 years. The disappointing performance of current treatment modalities makes it imperative to investigate alternative strategies against pancreatic cancer. Combinatorial chemoprevention using low doses of drugs has the potential to provide an answer in terms of arresting this fast-spreading disease even before it is initiated. Aspirin, curcumin and sulforaphane have recently received significant attention as chemopreventive agents, however, no group has investigated a combinatorial effect of these agents despite recent evidence of synergistic activity of many promising chemopreventive agents when administered in combination. Also, there is limited data in literature as to the optimal chemopreventive combinations, doses, efficacy, side effects and an ideal formulation strategy to deliver these chemopreventive agents against pancreatic cancer. The formulation strategy for pancreatic drug delivery is important to consider in order to elicit any type of a meaningful therapeutic response. Nanotechnology-based drug delivery systems are currently being evaluated to deliver chemopreventive combinations that would lower the doses with lesser chance of toxic side effects, while maintaining efficacy. The application of such a system has never been studied in pancreatic cancer. Thus, the overall goal of this pilot study is to develop an effective, low dose, novel combination of chemopreventive agents delivered using a unique nanotechnology-based delivery system for the prevention of pancreatic cancer.

描述（由申请人提供）： 胰腺癌是美国癌症死亡的第四大常见原因，每年有超过42，000人被诊断患有这种疾病。对于5年内生存机会<5%的受影响患者，预后极为严峻。目前治疗模式的令人失望的表现，使其迫切需要研究针对胰腺癌的替代策略。使用低剂量药物的组合化学预防有可能提供一个答案，甚至在开始之前就阻止这种快速传播的疾病。阿司匹林、姜黄素和萝卜硫素作为化学预防剂最近受到了极大的关注，然而，尽管最近有证据表明许多有前途的化学预防剂在联合给药时具有协同活性，但没有小组研究这些药物的组合效应。此外，文献中关于最佳化学预防组合、剂量、功效、副作用和递送这些化学预防剂对抗胰腺癌的理想制剂策略的数据有限。胰腺药物递送的制剂策略对于引起任何类型的有意义的治疗反应是重要的。目前正在评估基于纳米技术的药物输送系统，以提供化学预防组合，降低剂量，减少毒副作用的机会，同时保持疗效。这种系统在胰腺癌中的应用从未被研究过。因此，这项初步研究的总体目标是开发一种有效的、低剂量的、新型的化学预防剂组合，该组合使用独特的基于纳米技术的递送系统递送，用于预防胰腺癌。